Pressmeddelande

Acarix Named 2025 Digital Innovation Winner by Global Cardiovascular Awards

Malmö, Sweden — Acarix, a global leader in AI and acoustics-based cardiac diagnostics, has been awarded the 2025 Digital Innovation Award with the honorable mention for Innovation in Cardiac Imaging at the Global Cardiovascular Awards in London for its breakthrough CADScor® System.

The Digital Innovation Award honors pioneering use of digital, mobile, and AI technologies that are reshaping cardiovascular care. Acarix’s CADScor System is revolutionizing early cardiac diagnostics through a non-invasive, AI-driven approach that enables rapid and accurate risk assessment of coronary artery disease (CAD), empowering physicians to identify patients with stable chest pain who require further evaluation.

“We are proud to share that we were awarded the Digital Innovation Award and received an honorable mention for Innovation in Cardiac Imaging, one of only a handful of honorable mentions awarded. It is an honor to be acknowledged among the innovators advancing cardiovascular care globally,” said Aamir Mahmood, President and CEO of Acarix. “This award and honorable mention reflects our commitment to integrating advanced AI and acoustic technology to improve patient outcomes. With the CADScor System, clinicians can achieve over 96% certainty in low risk stratification, reducing unnecessary procedures and streamlining patient care pathways, which is a game-changer for both patients and healthcare providers.”

The Global Cardiovascular Awards are judged by a distinguished panel of international experts, including CEOs, clinical leaders, and key opinion leaders in cardiovascular and cardiothoracic medicine. Winners are selected through rigorous evaluation of innovations that demonstrate measurable impact on cardiovascular health worldwide.

Founded to spotlight those shaping the future of cardiovascular care, the Global Cardiovascular Awards celebrate outstanding contributions from researchers, clinicians, innovators, and organizations dedicated to advancing prevention, diagnosis, and treatment of cardiovascular disease.

###

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX) and cross-traded on the OTCQB market in the US (ticker: ACIXF). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com